[Mirapex (pramipexole) in the treatment of non-motor disturbances in Parkinson's disease].
The effect of the dopamine receptor antagonist mirapex on emotional disorders (anxiety, depression), cognitive disturbances and sleep disorders has been studied in 66 patients with Parkinson's disease. Mirapex has been administered in addition to levodopa and other antiparkinsonian drugs in dosage 3,5+/-1,1 mg daily to 36 patients with emotional and cognitive disorders and in dosage 2,9+/-0,96 mg daily to 30 patients with sleep disorders. Patient's state has been assessed using a number of psychometric scales and neuropsychological tests. The effectiveness of Mirapex in all disorders studied has been shown.
Nodel'
M R
MR
Iakhno
N N
NN
D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001007:Anxiety / Q000188:drug therapy* / Q000209:etiology; D052160:Benzothiazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D003863:Depression / Q000188:drug therapy* / Q000209:etiology; D004305:Dose-Response Relationship, Drug; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D010300:Parkinson Disease / Q000150:complications*; D000077487:Pramipexole; D017447:Receptors, Dopamine D1 / Q000819:agonists; D012893:Sleep Wake Disorders / Q000188:drug therapy* / Q000209:etiology; D016896:Treatment Outcome
D000978:Antiparkinson Agents; D052160:Benzothiazoles; D017447:Receptors, Dopamine D1; D000077487:Pramipexole